Advanced search
Publication Cover
Current Medical Research and Opinion Volume 33, 2017 - Issue 4
Submit an article Journal homepage
3,743
Views
31
CrossRef citations to date
0
Altmetric
Pulmomology

Frequency and costs of pulmonary exacerbations in patients with cystic fibrosis in the United States

Jaime L. RubinVertex Pharmaceuticals, Incorporated, Boston, MA, USA; Correspondence[email protected]
,
Sarah ThayerOptum, San Francisco, CA, USA;
,
Angela WatkinsOptum, Eden Prairie, MN, USA;
,
Jeffrey S. WagenerUniversity of Colorado Medical School, Aurora, CO, USA;
,
Paul S. HodgkinsVertex Pharmaceuticals, Incorporated, Boston, MA, USA;
&
Michael S. SchechterChildren’s Hospital of Richmond at Virginia Commonwealth University, VA, USA
Pages 667-674 | Received 19 Oct 2016, Accepted 21 Dec 2016, Published online: 09 Feb 2017

Citations (31)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Anne M. Akkerman-Nijland, Onno W. Akkerman, Floris Grasmeijer, Paul Hagedoorn, Henderik. W. Frijlink, Bart. L. Rottier, Gerard. H. Koppelman & Daniel. J. Touw. (2021) The pharmacokinetics of antibiotics in cystic fibrosis. Expert Opinion on Drug Metabolism & Toxicology 17:1, pages 53-68.
Read now
Ranjani Somayaji, Dave P Nichols & Scott C Bell. (2020) Cystic fibrosis – Ten promising therapeutic approaches in the current era of care. Expert Opinion on Investigational Drugs 29:10, pages 1107-1124.
Read now
Narelle S. Cox & Anne E. Holland. (2019) Current perspectives of physical activity in cystic fibrosis. Expert Review of Respiratory Medicine 13:1, pages 13-22.
Read now

Articles from other publishers (28)

Wendy HC Song, Kendrew SK Wong, David M. Goldfarb, Jeffrey N Bone & Jonathan H Rayment. (2024) Frequent microbiological surveillance during inpatient cystic fibrosis pulmonary exacerbations has limited clinical value. Journal of Cystic Fibrosis 23:2, pages 282-287.
Crossref
Zain M. Cheema, Lilian C. Gomez, Noah Johnson, Olivier D. Laflamme, Harvey R. Rabin, Kim Steele, John Wallenburg, Jeanette Leong, Stephanie Y. Cheng, Bradley S. Quon, Anne L. Stephenson, W. Dominika Wranik, Mohsen Sadatsafavi & Sanja Stanojevic. (2023) Measuring the burden of cystic fibrosis: A scoping review. Journal of Cystic Fibrosis.
Crossref
Ranjani Somayaji & Bradley S. Quon. (2023) Breath of fresh insight: unraveling the evolution of our understanding of cystic fibrosis pulmonary exacerbations. Current Opinion in Pulmonary Medicine 29:6, pages 587-594.
Crossref
Heba A. Ali, Mona A. Salem & Marwa A. Abdelwahad. (2023) Prognostic factors of pulmonary exacerbations severity in pediatric bronchiectasis: a retrospective cohort study. Egyptian Pediatric Association Gazette 71:1.
Crossref
Ryan C. Perkins & Gregory S. Sawicki. (2023) High deductible insurance plans impart economic burden for people with cystic fibrosis. Pediatric Pulmonology 58:6, pages 1798-1801.
Crossref
Aaron C Miller, Logan M Harris, Joseph E Cavanaugh, Mahmoud Abou Alaiwa, David A Stoltz, Douglas B Hornick & Philip M Polgreen. (2022) The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor. Clinical Infectious Diseases 75:7, pages 1115-1122.
Crossref
Laura S. Gold, Ryan N. Hansen, Donald L. Patrick, Ashley Tabah, Sonya L. Heltshe, Patrick A. Flume, Christopher H. Goss, Natalie E. West, Don B. Sanders, Donald R. VanDevanter & Larry Kessler. (2022) Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations. Journal of Cystic Fibrosis 21:4, pages 594-599.
Crossref
Natalie Franz, Hannah Rapp, Ryan N. Hansen, Laura S. Gold, Christopher H. Goss, Noah Lechtzin & Larry G. Kessler. (2022) Health care costs related to home spirometry in the eICE randomized trial. Journal of Cystic Fibrosis 21:1, pages 61-69.
Crossref
Georgene E. Hergenroeder & Jonathan D. Cogen. (2021) Exasperation with the lack of pulmonary exacerbation treatment standardization. Journal of Cystic Fibrosis 20:6, pages 901-903.
Crossref
Eden J. VanDevanter, Sonya L. Heltshe, Michelle Skalland, Noah Lechtzin, Dave Nichols & Christopher H. Goss. (2021) The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis. Journal of Cystic Fibrosis 20:6, pages 932-936.
Crossref
Teja Thorat, Lisa J. McGarry, Machaon M. Bonafede, Brendan L. Limone, Jaime L. Rubin, Krutika Jariwala‐Parikh & Michael W. Konstan. (2021) Healthcare resource utilization and costs among children with cystic fibrosis in the United States. Pediatric Pulmonology 56:9, pages 2833-2844.
Crossref
Ryan C. Perkins, Mahek Shah & Gregory S. Sawicki. (2021) An evaluation of healthcare utilization and clinical charges in children and adults with cystic fibrosis. Pediatric Pulmonology 56:5, pages 928-938.
Crossref
Rosa María Girón Moreno, Marta García-Clemente, Layla Diab-Cáceres, Adrián Martínez-Vergara, Miguel Ángel Martínez-García & Rosa Mar Gómez-Punter. (2021) Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics 10:5, pages 486.
Crossref
Niamh E. Harrington, Esther Sweeney & Freya Harrison. (2020) Building a better biofilm - Formation of in vivo-like biofilm structures by Pseudomonas aeruginosa in a porcine model of cystic fibrosis lung infection. Biofilm 2, pages 100024.
Crossref
Charlie McLeod, Jamie Wood, André Schultz, Richard Norman, Sherie Smith, Christopher C. Blyth, Steve Webb, Alan R. Smyth & Thomas L. Snelling. (2020) Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: A systematic review. Journal of Cystic Fibrosis 19:6, pages 858-867.
Crossref
Garrett Pehote & Neeraj Vij. (2020) Autophagy Augmentation to Alleviate Immune Response Dysfunction, and Resolve Respiratory and COVID-19 Exacerbations. Cells 9:9, pages 1952.
Crossref
Koliarne Tong, Daniel Barker, Megan France, Lucy Burr, Hugh Greville, Simone Visser, Peter Middleton, Claire Wainwright, Douglas Dorahy & Peter Wark. (2020) Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease. Journal of Cystic Fibrosis 19:3, pages 415-420.
Crossref
Laura S. Gold, Donald L. Patrick, Ryan N. Hansen, Christopher H. Goss & Larry Kessler. (2019) Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary–Chronic Respiratory Infection Symptom Score (CFRSD-CRISS). Journal of Cystic Fibrosis 18:6, pages 886-893.
Crossref
Mark A. Tesell, Caroline J. Alper, Rachel Bacon, Bonnie C. Greenwood, Kimberly Lenz, Paul L. Jeffrey & Karen Stevens. (2019) Effect of Lumacaftor/Ivacaftor on Pulmonary Exacerbation Rates in Members with Cystic Fibrosis in a Medicaid Population. Journal of Managed Care & Specialty Pharmacy 25:9, pages 1021-1025.
Crossref
Zhe Hui Hoo, Nicole R. Bramley, Rachael Curley, Frank P. Edenborough, Stephen J. Walters, Michael J. Campbell & Martin J. Wildman. (2019) Intravenous antibiotic use and exacerbation events in an adult cystic fibrosis centre: A prospective observational study. Respiratory Medicine 154, pages 109-115.
Crossref
Bishal Mohindru, David Turner, Tracey Sach, Diana Bilton, Siobhan Carr, Olga Archangelidi, Arjun Bhadhuri & Jennifer A. Whitty. (2019) Health economic modelling in Cystic Fibrosis: A systematic review. Journal of Cystic Fibrosis 18:4, pages 452-460.
Crossref
Lenycia de Cassya Lopes Neri, Monica Taminato & Luiz Vicente Ribeiro Ferreira da Silva Filho. (2019) Systematic Review of Probiotics for Cystic Fibrosis Patients. Journal of Pediatric Gastroenterology and Nutrition 68:3, pages 394-399.
Crossref
Dolly Sharma, Shan Xing, Yu-Ting Hung, Rachel N. Caskey, Maria L. Dowell & Daniel R. Touchette. (2018) Cost-effectiveness analysis of lumacaftor and ivacaftor combination for the treatment of patients with cystic fibrosis in the United States. Orphanet Journal of Rare Diseases 13:1.
Crossref
David M. Orenstein & Robert N. Abood. (2018) Cost(s) of caring for patients with cystic fibrosis. Current Opinion in Pediatrics 30:3, pages 393-398.
Crossref
Erin M. Crowley, Gabriel T. Bosslet, Babar Khan, Mary Ciccarelli & Cynthia D. Brown. (2018) Impact of social complexity on outcomes in cystic fibrosis after transfer to adult care. Pediatric Pulmonology 53:6, pages 735-740.
Crossref
Katelyn Krivchenia, Dmitry Tumin, Christopher J. Nemastil, Joseph D. Tobias & Don HayesJr.Jr.. (2018) Timing of Spirometry May Impact Hospital Length of Stay for Cystic Fibrosis Pulmonary Exacerbation. Lung 196:2, pages 207-211.
Crossref
Donald R. VanDevanter, Marcia L. Craib, David J. Pasta, Stefanie J. Millar, Wayne J. Morgan & Michael W. Konstan. (2017) Cystic fibrosis clinical characteristics associated with dornase alfa treatment regimen change. Pediatric Pulmonology 53:1, pages 43-49.
Crossref
L. Keith Scott & Robert Toner. (2017) Clinically Promising Biomarkers in Cystic Fibrosis Pulmonary Exacerbations. Lung 195:4, pages 397-401.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.